Finland-based biopharmaceutical company Faron Pharmaceuticals Ltd (AIM:FARN) (First North:FARON) declared on Monday that it will progress its lead asset bexmarilimab, a novel precision cancer immunotherapy, into a registrational Phase 2/3 trial in treatment-naïve higher-risk myelodysplastic syndrome (HR-MDS), following positive feedback from the US Food and Drug Administration (FDA).
The FDA advised the company to prioritise frontline development, which could enable approval across the entire HR-MDS population. The planned study will evaluate bexmarilimab in combination with azacitidine, beginning with a dose optimisation run-in comparing 1 mg/kg and 3 mg/kg regimens before moving seamlessly into the registrational stage.
Accelerated approval will be sought based on interim data from frontline patients, with composite complete remission (CR + CReq) confirmed by the FDA as an acceptable primary endpoint under IWG 2023 criteria. Overall Survival will serve as a co-primary endpoint, while composite complete remission (cCR) will be assessed as a key secondary measure.
The FDA also endorsed Faron's non-clinical and manufacturing plans, clearing the path toward regulatory submission.
Bexmarilimab is a wholly-owned precision immunotherapy designed to reprogramme macrophages by targeting the Clever-1 receptor, reversing immunosuppression, and enhancing response to standard of care therapies. It is currently being investigated in the ongoing BEXMAB Phase I/II trial in acute myeloid leukemia and MDS.
Faron is focused on advancing novel immunotherapies to expand the impact of cancer treatment by harnessing the immune system.
Soligenix' dusquetide granted US FDA orphan drug designation to treat Behcet's Disease
WuXi Biologics Ireland facility granted European approval to manufacture innovative biologic
Unicycive Therapeutics secures US patent for UNI-494 in chronic kidney disease
GoodRx partners with Novo Nordisk to offer Ozempic and Wegovy at USD499 per month
Faron to advance bexmarilimab into registrational Phase 2/3 trial after FDA endorsement
Basilea Pharmaceutica enters exclusive license agreement with Venatorx Pharmaceuticals
Nanoscope Therapeutics announces positive results from STARLIGHT clinical trial
Leads Biolabs completes patient enrollment in pivotal Opamtistomig trial for EP-NEC
Remegen's Telitacicept meets Sjogren's syndrome Phase III trial's primary endpoint
Phosphorex appoints chief executive officer
CuraCell secures German regulatory clearance for clinical trial of CC-38 TIL therapy
Insmed's BRINSUPRI (brensocatib) non-cystic fibrosis bronchiectasis treatment approved by US FDA
Ocular Therapeutix secures FDA special protocol assessment for AXPAXLI NPDR trial
Novartis reports positive Phase III trial results for ianalumab in immune thrombocytopenia